Fenretinide in the prevention of breast cancer in premenopausal women: Fluke or fact?

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1035-1036

  Pritchard, Kathy I ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FENRETINIDE; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RECURRENCE; CLINICAL OBSERVATION; CLINICAL TRIAL; DATA ANALYSIS; DRUG SAFETY; EDITORIAL; EXPERIMENTAL DESIGN; FEMALE; HUMAN; MASTECTOMY; MEDICAL LITERATURE; PREMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION;

EID: 33745605212     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl115     Document Type: Editorial

References (12)

1. Veronesi U, Mariani L, Decensi A et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006; 17: 807-812.
2. Verinesum U, De Palo G, Marubini E et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999; 91: 1847-1856.
3. Menard S, Camerini T, Mariani L et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 2001; 93: 240-241.
4. Guerrieri-Gonzaga A, Robertson C, Bonanni B et al. Preliminary results on safety and activity of a randomized double-blind 2×2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol. 2006; 24: 129-135.
5. Pellegrini R, Mariotto A, Tagliabue E et al. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ. 1995; 6: 863-869.
6. De Palo G, Mariani L, Camerini T et al. Effect of fenretinide on ovarian carcinoma occurrence. Gyne Oncol 2002; 86: 24-27.
7. Simeone AM, Deng CX, Kelloff GJ et al. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis 2005; 26: 1000-1007.
8. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
9. IBIS investigators. First results from the International breast cancer intervention study (IBIS-I): A randomized prevention trial. Lancet 2002; 360: 817-824.
10. National Cancer Institute. The Study of Tamoxifen and Raloxifene (STAR): Questions and Answers. www.nsabp.pitt.edu 2006.
11. Powles TJ. Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer. NSABP Protocol P-2. J Natl Cancer Inst 1999; 91: 730.
12. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19: 881-894.